Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock.
Pollack
M
M
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4799, USA.
Ohl
C A
CA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000502:physiology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000276:immunology; D008074:Lipoproteins / Q000097:blood; D008565:Membrane Proteins; D018805:Sepsis / Q000517:prevention & control / Q000628:therapy*; D012772:Shock, Septic / Q000517:prevention & control / Q000628:therapy*
D000911:Antibodies, Monoclonal; D023181:Antimicrobial Cationic Peptides; D001798:Blood Proteins; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008074:Lipoproteins; D008565:Membrane Proteins; C021623:bactericidal permeability increasing protein